Copyright Reports & Markets. All rights reserved.

Global PD-1 and PD-L1 Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global PD-1 and PD-L1 Inhibitors Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 PD-1 Inhibitors
    • 1.3.3 PD-L1 Inhibitors
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global PD-1 and PD-L1 Inhibitors Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Solid Tumors
    • 1.4.3 Blood-related Tumors
  • 1.5 Global PD-1 and PD-L1 Inhibitors Market Size & Forecast
    • 1.5.1 Global PD-1 and PD-L1 Inhibitors Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global PD-1 and PD-L1 Inhibitors Sales Quantity (2019-2030)
    • 1.5.3 Global PD-1 and PD-L1 Inhibitors Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Merck
    • 2.1.1 Merck Details
    • 2.1.2 Merck Major Business
    • 2.1.3 Merck PD-1 and PD-L1 Inhibitors Product and Services
    • 2.1.4 Merck PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Merck Recent Developments/Updates
  • 2.2 Bristol-Myers Squibb
    • 2.2.1 Bristol-Myers Squibb Details
    • 2.2.2 Bristol-Myers Squibb Major Business
    • 2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product and Services
    • 2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Bristol-Myers Squibb Recent Developments/Updates
  • 2.3 Roche
    • 2.3.1 Roche Details
    • 2.3.2 Roche Major Business
    • 2.3.3 Roche PD-1 and PD-L1 Inhibitors Product and Services
    • 2.3.4 Roche PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Roche Recent Developments/Updates
  • 2.4 AstraZeneca
    • 2.4.1 AstraZeneca Details
    • 2.4.2 AstraZeneca Major Business
    • 2.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Product and Services
    • 2.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 AstraZeneca Recent Developments/Updates
  • 2.5 Ono Pharmaceutical
    • 2.5.1 Ono Pharmaceutical Details
    • 2.5.2 Ono Pharmaceutical Major Business
    • 2.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product and Services
    • 2.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Ono Pharmaceutical Recent Developments/Updates
  • 2.6 Regeneron
    • 2.6.1 Regeneron Details
    • 2.6.2 Regeneron Major Business
    • 2.6.3 Regeneron PD-1 and PD-L1 Inhibitors Product and Services
    • 2.6.4 Regeneron PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Regeneron Recent Developments/Updates
  • 2.7 Innovent
    • 2.7.1 Innovent Details
    • 2.7.2 Innovent Major Business
    • 2.7.3 Innovent PD-1 and PD-L1 Inhibitors Product and Services
    • 2.7.4 Innovent PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Innovent Recent Developments/Updates
  • 2.8 Hengrui Medicine
    • 2.8.1 Hengrui Medicine Details
    • 2.8.2 Hengrui Medicine Major Business
    • 2.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product and Services
    • 2.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Hengrui Medicine Recent Developments/Updates
  • 2.9 Junshi Biosciences
    • 2.9.1 Junshi Biosciences Details
    • 2.9.2 Junshi Biosciences Major Business
    • 2.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product and Services
    • 2.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Junshi Biosciences Recent Developments/Updates
  • 2.10 Merck KGaA
    • 2.10.1 Merck KGaA Details
    • 2.10.2 Merck KGaA Major Business
    • 2.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Product and Services
    • 2.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Merck KGaA Recent Developments/Updates

3 Competitive Environment: PD-1 and PD-L1 Inhibitors by Manufacturer

  • 3.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturer (2019-2024)
  • 3.3 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of PD-1 and PD-L1 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 PD-1 and PD-L1 Inhibitors Manufacturer Market Share in 2023
    • 3.4.3 Top 6 PD-1 and PD-L1 Inhibitors Manufacturer Market Share in 2023
  • 3.5 PD-1 and PD-L1 Inhibitors Market: Overall Company Footprint Analysis
    • 3.5.1 PD-1 and PD-L1 Inhibitors Market: Region Footprint
    • 3.5.2 PD-1 and PD-L1 Inhibitors Market: Company Product Type Footprint
    • 3.5.3 PD-1 and PD-L1 Inhibitors Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global PD-1 and PD-L1 Inhibitors Market Size by Region
    • 4.1.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2019-2030)
    • 4.1.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Region (2019-2030)
    • 4.1.3 Global PD-1 and PD-L1 Inhibitors Average Price by Region (2019-2030)
  • 4.2 North America PD-1 and PD-L1 Inhibitors Consumption Value (2019-2030)
  • 4.3 Europe PD-1 and PD-L1 Inhibitors Consumption Value (2019-2030)
  • 4.4 Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value (2019-2030)
  • 4.5 South America PD-1 and PD-L1 Inhibitors Consumption Value (2019-2030)
  • 4.6 Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 5.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Type (2019-2030)
  • 5.3 Global PD-1 and PD-L1 Inhibitors Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 6.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Application (2019-2030)
  • 6.3 Global PD-1 and PD-L1 Inhibitors Average Price by Application (2019-2030)

7 North America

  • 7.1 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 7.2 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 7.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
    • 7.3.1 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2019-2030)
    • 7.3.2 North America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 8.2 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 8.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
    • 8.3.1 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe PD-1 and PD-L1 Inhibitors Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size by Region
    • 9.3.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 10.2 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 10.3 South America PD-1 and PD-L1 Inhibitors Market Size by Country
    • 10.3.1 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2019-2030)
    • 10.3.2 South America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size by Country
    • 11.3.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 PD-1 and PD-L1 Inhibitors Market Drivers
  • 12.2 PD-1 and PD-L1 Inhibitors Market Restraints
  • 12.3 PD-1 and PD-L1 Inhibitors Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of PD-1 and PD-L1 Inhibitors and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of PD-1 and PD-L1 Inhibitors
  • 13.3 PD-1 and PD-L1 Inhibitors Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 PD-1 and PD-L1 Inhibitors Typical Distributors
  • 14.3 PD-1 and PD-L1 Inhibitors Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
    According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Inhibitors market size was valued at US$ 49610 million in 2023 and is forecast to a readjusted size of USD 172690 million by 2030 with a CAGR of 19.7% during review period.
    North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
    This report is a detailed and comprehensive analysis for global PD-1 and PD-L1 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global PD-1 and PD-L1 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
    Global PD-1 and PD-L1 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
    Global PD-1 and PD-L1 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
    Global PD-1 and PD-L1 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (L), and ASP (USD/ml), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for PD-1 and PD-L1 Inhibitors
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global PD-1 and PD-L1 Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, Merck KGaA, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    PD-1 and PD-L1 Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    PD-1 Inhibitors
    PD-L1 Inhibitors
    Market segment by Application
    Solid Tumors
    Blood-related Tumors
    Major players covered
    Merck
    Bristol-Myers Squibb
    Roche
    AstraZeneca
    Ono Pharmaceutical
    Regeneron
    Innovent
    Hengrui Medicine
    Junshi Biosciences
    Merck KGaA
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe PD-1 and PD-L1 Inhibitors product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of PD-1 and PD-L1 Inhibitors, with price, sales quantity, revenue, and global market share of PD-1 and PD-L1 Inhibitors from 2019 to 2024.
    Chapter 3, the PD-1 and PD-L1 Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the PD-1 and PD-L1 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and PD-1 and PD-L1 Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Inhibitors.
    Chapter 14 and 15, to describe PD-1 and PD-L1 Inhibitors sales channel, distributors, customers, research findings and conclusion.

    Buy now